Incyte Corporation has published a document highlighting data on myeloproliferative neoplasms (MPNs) from the EHA 2025 event. The document includes insights into essential thrombocythemia, research on mutant calreticulin in MPNs, and phase 1 data on a novel monoclonal antibody targeting mutant calreticulin. The full document can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief on June 15, 2025, and is solely responsible for the information contained therein.